MCID: PLM035
MIFTS: 49

Pulmonary Eosinophilia

Categories: Blood diseases, Respiratory diseases

Aliases & Classifications for Pulmonary Eosinophilia

MalaCards integrated aliases for Pulmonary Eosinophilia:

Name: Pulmonary Eosinophilia 12 54 15 71
Asthmatic Pulmonary Eosinophilia 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9498
ICD9CM 34 518.3
MeSH 44 D011657
SNOMED-CT 67 196145005
ICD10 32 J82
UMLS 71 C0034068 C0340076

Summaries for Pulmonary Eosinophilia

Disease Ontology : 12 A hypereosinophilic syndrome characterized by the accumulation of eosinophils in the lungs.

MalaCards based summary : Pulmonary Eosinophilia, also known as asthmatic pulmonary eosinophilia, is related to chronic eosinophilic pneumonia and loeffler syndrome, and has symptoms including hemoptysis An important gene associated with Pulmonary Eosinophilia is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Omalizumab and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include t cells, lung and bone marrow, and related phenotypes are hematopoietic system and immune system

Related Diseases for Pulmonary Eosinophilia

Diseases related to Pulmonary Eosinophilia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 293)
# Related Disease Score Top Affiliating Genes
1 chronic eosinophilic pneumonia 32.2 RNASE3 IL5 CCL5 CCL3 CCL11
2 loeffler syndrome 32.1 IL5 IL13 CCR3
3 ascaris lumbricoides infection 31.7 IL5 IL13 CXCL8
4 eosinophilic pneumonia 30.8 SFTPD RNASE3 IL5 IL4 IL13 CXCL8
5 cytokine deficiency 30.7 IL5 IL13
6 filarial elephantiasis 30.7 IL5 IL4 IL13
7 toxocariasis 30.3 RNASE3 IL5 IL4 IL13
8 elephantiasis 30.3 RNASE3 IL5 IL4 IL13
9 folliculitis 29.9 IL5 IL4 CCL5 CCL11
10 respiratory syncytial virus infectious disease 29.9 IL5 IL13 CCL5 CCL3
11 chronic asthma 29.8 RNASE3 IL5 IL4 IL13 CCL11
12 pneumoconiosis 29.6 SERPINA1 IL4 CXCL8
13 crohn's disease 29.5 IL4 IL13 CXCL8 CSF2
14 bronchiolitis obliterans 29.4 SFTPD IL13 CXCL8
15 leprosy 3 29.4 IL5 IL4 IL13 CXCL8 CSF2
16 sarcoidosis 1 29.4 SFTPD IL13 CCL5 CCL3 CCL11
17 pulmonary fibrosis 29.3 SFTPD IL13 CXCL8 CCL3 CCL17
18 churg-strauss syndrome 29.3 RNASE3 PRG2 IL5 CYSLTR1 CXCL8 CCL17
19 allergic bronchopulmonary aspergillosis 29.2 SFTPD IL5 IL4 EPX CCR3 CCL17
20 hypereosinophilic syndrome 29.1 RNASE3 PRG2 IL5 IL4 IL13 EPX
21 allergic asthma 29.1 RNASE3 IL5 IL4 IL13 EPX CXCL8
22 interstitial lung disease 28.9 SFTPD IL5 IL4 IL13 CXCL8 CSF2
23 aspergillosis 28.8 SFTPD IL5 IL4 EPX CXCL8 CSF2
24 bronchitis 28.7 SERPINA1 RNASE3 IL5 IL4 IL13 CXCL8
25 pulmonary hypertension 28.6 SERPINA1 PDE4A IL13 CXCL8 CSF2 CCL5
26 bronchiolitis 28.5 SFTPD RNASE3 IL5 IL4 IL13 CXCL8
27 allergic disease 28.4 RNASE3 RNASE2 PRG2 IL5 IL4 IL13
28 rhinitis 28.0 RNASE3 PRG2 IL5 IL4 IL13 EPX
29 lung disease 27.8 SFTPD SERPINA1 RNASE3 PDE4A IL5 IL4
30 allergic rhinitis 27.6 RNASE3 IL5 IL4 IL13 EPX CXCL8
31 pneumonia 27.4 SFTPD SERPINA1 IL5 IL4 IL13 CXCL8
32 respiratory failure 27.2 SFTPD SERPINA1 RNASE3 PDE4A IL5 IL13
33 asthma 25.6 SFTPD SERPINA1 RNASE3 RNASE2 PRG2 PDE4A
34 filariasis 10.4
35 aztreonam allergy 10.4 IL5 IL13
36 cefaclor allergy 10.4 IL5 IL13
37 cefuroxime allergy 10.4 IL5 IL13
38 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4 IL5 IL13
39 ceftriaxone allergy 10.4 IL5 IL13
40 idiopathic eosinophilic pneumonia 10.4
41 allergic encephalomyelitis 10.3 CCL5 CCL3
42 cow milk allergy 10.3 IL5 IL4
43 whiplash 10.3 CCL5 CCL3
44 pemphigoid gestationis 10.3 RNASE3 IL5 CCL11
45 acute asthma 10.3 RNASE3 IL5 IL4
46 orange allergy 10.3 IL5 IL13
47 type 1 diabetes mellitus 22 10.3 CCL5 CCL3
48 cough variant asthma 10.3 RNASE3 IL5 IL4
49 toxic oil syndrome 10.3 IL5 IL4
50 vasomotor rhinitis 10.3 RNASE3 IL5 IL13

Comorbidity relations with Pulmonary Eosinophilia via Phenotypic Disease Network (PDN): (show all 13)


Active Peptic Ulcer Disease Acute Cystitis
Bronchitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Iron Deficiency Anemia Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Pulmonary Eosinophilia:



Diseases related to Pulmonary Eosinophilia

Symptoms & Phenotypes for Pulmonary Eosinophilia

UMLS symptoms related to Pulmonary Eosinophilia:


hemoptysis

MGI Mouse Phenotypes related to Pulmonary Eosinophilia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.9 CCL11 CCL17 CCL5 CCR3 CSF2 EPX
2 immune system MP:0005387 9.77 CCL11 CCL17 CCL5 CCR3 CSF2 CYSLTR1
3 respiratory system MP:0005388 9.28 CCL11 CCR3 CSF2 CYSLTR1 IL13 IL4

Drugs & Therapeutics for Pulmonary Eosinophilia

Drugs for Pulmonary Eosinophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4 242138-07-4
2
Azithromycin Approved Phase 4 83905-01-5 55185 447043
3
Budesonide Approved Phase 4 51333-22-3 63006 5281004
4
Reslizumab Approved, Investigational Phase 4 241473-69-8
5 Benralizumab Approved, Investigational Phase 4 1044511-01-4
6
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
9
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
10
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
11
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
12
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
13
tannic acid Approved Phase 4 1401-55-4
14
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
15 Gastrointestinal Agents Phase 4
16 Neuroprotective Agents Phase 4
17 Antiemetics Phase 4
18 Anti-Allergic Agents Phase 4
19 Anti-Infective Agents Phase 4
20 Antiviral Agents Phase 4
21 Anti-Bacterial Agents Phase 4
22 Formoterol Fumarate Phase 4
23 Budesonide, Formoterol Fumarate Drug Combination Phase 4
24 Respiratory System Agents Phase 4
25 Anti-Asthmatic Agents Phase 4
26 Adrenergic beta-Agonists Phase 4
27 Anti-Inflammatory Agents Phase 4
28 Neurotransmitter Agents Phase 4
29 Hormone Antagonists Phase 4
30 Hormones Phase 4
31 Adrenergic Agents Phase 4
32 Albuterol Phase 4
33 Immunoglobulins Phase 4
34 Bronchodilator Agents Phase 4
35 Tocolytic Agents Phase 4
36 glucocorticoids Phase 4
37 Antibodies Phase 4
38 Antibodies, Monoclonal Phase 4
39 Adrenergic Agonists Phase 4
40 Methylprednisolone Acetate Phase 4
41 Antineoplastic Agents, Hormonal Phase 4
42 Pharmaceutical Solutions Phase 3
43 Immunoglobulins, Intravenous Phase 3
44 Immunoglobulin G Phase 3
45
Fluticasone Approved, Experimental Phase 2 90566-53-3 62924
46
Pramipexole Approved, Investigational Phase 2 104632-26-0 59868 119570
47
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
48
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
49
Salmeterol xinafoate Phase 2 94749-08-3 56801
50 Fluticasone-Salmeterol Drug Combination Phase 2

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Unknown status NCT03652376 Phase 4 Benralizumab
2 A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study) Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
3 Phase 4, Randomized Study of Three Months-prednisolone Therapy in the Treatment of Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
4 How to "Choosebetweenamab" for Severe Asthma, Comparing Treatment With Mepolizumab and Omalizumab for Patients With Severe Allergic and Eosinophilic Asthma. Recruiting NCT04585997 Phase 4 Mepolizumab;Omalizumab
5 Effects of Azithromycin Treatment on Anti-viral Immunity in Patients With Asthma and COPD - A Randomized Double-blind, Placebo-controlled Trial Recruiting NCT04319705 Phase 4 Azithromycin;Placebo oral tablet
6 A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil Recruiting NCT04228588 Phase 4 Mepolizumab 100 MG [Nucala]
7 SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab Recruiting NCT04159519 Phase 4 Symbicort®;Fasenra®;Ventolin®
8 Predictive Signature of Benralizumab Response Not yet recruiting NCT04565483 Phase 4 Benralizumab Prefilled Syringe
9 Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma and Persistent Sputum Eosinophilia Despite Standard Dose Therapy Not yet recruiting NCT04710134 Phase 4
10 A Phase 4, Open-label, Single Arm, 24-week, Phase 4 Study to Evaluate the Safety and Efficacy of Mepolizumab 100 mg SC Administered Every 4 Weeks in Indian Participants Aged >=18 Years With Severe Eosinophilic Asthma Requiring Oral Corticosteroid Treatment to Maintain Asthma Control (PRISM) Not yet recruiting NCT04276233 Phase 4 Prednisone/ Prednisolone;Salbutamol
11 A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3 Reslizumab;Placebo
12 A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01285323 Phase 3 Reslizumab;Placebo
13 A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3 Reslizumab;Placebo
14 A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810) Completed NCT02555371 Phase 3 Placebo
15 Route of Administration of Anti-IL5 Monoclonal Antibody in Prednisone-dependent Eosinophilic Asthma Completed NCT02559791 Phase 2, Phase 3 Placebo
16 A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3 Reslizumab;Placebo
17 A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3 Placebo;SOC
18 An Open-label Study to Evaluate the Pharmacokinetics and Pharmacodynamics and Long-term Safety of Benralizumab Administered Subcutaneously in Children With Severe Eosinophilic Asthma Recruiting NCT04305405 Phase 3 Benralizumab
19 Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies Recruiting NCT03470311 Phase 3
20 A 52 Week, Randomised, Double Blind, Multinational, Multicentre, 4-arm Parallel Group Trial to Assess the Efficacy and Safety of 3 Doses of CHF 6532 Compared to Placebo on Top of Standard of Care in Patients With Uncontrolled Severe Eosinophilic Asthma Recruiting NCT04049175 Phase 3 Treatment A;Treatment B;Treatment C;Treatment D
21 A Randomized, Double-blind, Placebo-controlled, Mono-center Study to Evaluate the Effects of Mepolizumab on Airway Physiology in Patients With Eosinophilic Asthma: the MEMORY Study Terminated NCT02594332 Phase 3 Mepolizumab;Placebo
22 An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma Terminated NCT01290887 Phase 3 Reslizumab
23 An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Terminated NCT03052725 Phase 3 reslizumab
24 Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy Completed NCT01312961 Phase 2 Dupilumab;Placebo (for Dupilumab);Fluticasone/Salmeterol combination therapy;Fluticasone monotherapy;Albuterol;Levalbuterol
25 Placebo Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma Completed NCT03469934 Phase 2 ANB020;Placebo
26 A Phase IIa , Double-blind, Placebo-controlled Dose-ranging Study to Evaluate the Efficacy and Safety of KHK4563 in Adults With Uncontrolled, Suspected Eosinophilic Asthma Completed NCT01412736 Phase 2 KHK4563;KHK4563;KHK4563;Placebo
27 The Effect of OC000459 on Eosinophilic Airway Inflammation and Asthma Control in Subjects With Refractory Eosinophilic Asthma: a Randomised, Double-blind, Placebo Controlled Trial Completed NCT02560610 Phase 2 OC000459;Placebo
28 A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Biomarker Study of the Effects of Dexpramipexole on Eosinophils in Subjects With Eosinophilic Asthma Active, not recruiting NCT04046939 Phase 2 dexpramipexole 75 mg/day;dexpramipexole 150 mg/day;dexpramipexole 300 mg/day;placebo oral tablet
29 Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Efficacy and Safety of XC8 in Patients With the Eosinophilic Phenotype of Bronchial Asthma Not yet recruiting NCT04674137 Phase 2 XC8 100 mg;Placebo
30 A Randomized, Double-blind, Placebo-controlled Parallel Trial of Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody by Single Subcutaneous Injection in Healthy Subjects Recruiting NCT04445038 Phase 1 610;Placebo
31 Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Community Acquired Pneumonia Unknown status NCT01152424
32 A Prospective Observational Study on the Effect of Mepolizumab add-on Therapy on Daily Physical Activity in Patients With Severe Eosinophilic Asthma Unknown status NCT03739320 Mepolizumab 100 MG Injection [Nucala]
33 Serum Cytokine Profiles of Severe Asthma Completed NCT03563521
34 Effet du Mepolizumab Sur la décroissance de la corticothérapie systémique Chez Des Patients Avec un Asthme éosinophilique sévère Etude Observationnelle, Suivi de Cohorte Via Une ATU Nominative Completed NCT03453021 Mepolizumab
35 Effects of Anti-IL5 Biological Treatments of Total Blood IgE Levels in Severe Asthmatic Patients: Real-life Retrospective Multicenter Observational Study Completed NCT04181190
36 Characteristics of the Eosinophilic Asthma Phenotype: an Observational Study in Patients From a Tertiary Care Center With Various Asthma Severities: The Quebec Heart and Lung Institute-Laval University Retrospective Asthma Database Analysis Completed NCT03696914
37 Observational Retrospective Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain Completed NCT04126499
38 Identification of Autoantigens and Their Potential Post-translational Modification in EGPA and Severe Eosinophilic Asthma Recruiting NCT04671446
39 Efficacy of Mepolizumab in Patients With Late-onset Severe Eosinophilic Asthma and Fixed Obstruction Recruiting NCT04612556 Mepolizumab 100 MG [Nucala]
40 Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma Recruiting NCT04542902
41 Orphans Unite: chILD Better Together - European Management Platform for Childhood Interstitial Lung Diseases / chILD-EU - International Register and Biobank for Children´s Interstital Lung Disease Recruiting NCT02852928
42 A Multicentre Single Arm Observational Prospective Study to Assess Demographic Characteristics Burden of Disease PRO's in Uncontrolled, Severe Eosinophilic Asthma Patients Aged 18y or Older and Qualifying for Treatment With Benralizumab in BE Recruiting NCT04221802
43 Peripheral Eosinophils Phenotypes in Airway Inflammatory Diseases: Towards Proper Clustering and Therapeutic Targeting Recruiting NCT04187976
44 Computed Tomography Air-trapping Characterisation for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients Recruiting NCT03976310 48 weeks of Benralizumab
45 Utilisation of Benralizumab in the Clinical Practise in Severe Eosinophilic Asthma Patients in Switzerland Recruiting NCT03907137
46 Patient Outcomes Real World Evidence Registry (POWER): Patient Reported Outcomes in a Cohort of Canadian Adults With Severe Eosinophilic Asthma on Benralizumab. Recruiting NCT03833141
47 imPROve-asthma - A Prospective, 24-month, Observational Study to Investigate the Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Biologic Therapy Under Real-life Conditions in Germany Recruiting NCT04184284
48 Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils Recruiting NCT04538937
49 FUNLUM: Functional Lung MRI for Early Treatment Response Assessment and Outcome Prediction for Patients With Severe Eosinophilic Asthma on Anti IL 5 Antibody Therapy Recruiting NCT04512521 Mepolizumab
50 Description of Eosinophilic Pneumonia in BJI/PJI Treated by Daptomycin Recruiting NCT04414137

Search NIH Clinical Center for Pulmonary Eosinophilia

Genetic Tests for Pulmonary Eosinophilia

Anatomical Context for Pulmonary Eosinophilia

MalaCards organs/tissues related to Pulmonary Eosinophilia:

40
T Cells, Lung, Bone Marrow, Myeloid, Spleen, Thymus, Endothelial

Publications for Pulmonary Eosinophilia

Articles related to Pulmonary Eosinophilia:

(show top 50) (show all 788)
# Title Authors PMID Year
1
Clinical alterations and mRNA levels of IL-4 and IL-5 in bronchoalveolar cells of horses with transient pulmonary eosinophilia. 54 61
17996260 2008
2
Tropical pulmonary eosinophilia: pathogenesis, diagnosis and management. 54 61
17940489 2007
3
Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). 61 54
16120093 2005
4
Genetic polymorphisms of eosinophil-derived neurotoxin and eosinophil cationic protein in tropical pulmonary eosinophilia. 54 61
16014847 2005
5
Susceptibility of mice genetically deficient in the surfactant protein (SP)-A or SP-D gene to pulmonary hypersensitivity induced by antigens and allergens of Aspergillus fumigatus. 54 61
15905537 2005
6
Safety and efficacy of immune-stimulating complex-based antigen delivery systems for neonatal immunisation against respiratory syncytial virus infection. 61 54
15158774 2004
7
Allergen-induced fluctuation in CC chemokine receptor 3 expression on bone marrow CD34+ cells from asthmatic subjects: significance for mobilization of haemopoietic progenitor cells in allergic inflammation. 54 61
12871220 2003
8
Elevated immunoglobulin E against recombinant Brugia malayi gamma-glutamyl transpeptidase in patients with bancroftian filariasis: association with tropical pulmonary eosinophilia or putative immunity. 54 61
12540554 2003
9
Glucocorticoid administration accelerates mortality of pneumovirus-infected mice. 54 61
11740726 2001
10
Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma. 61 54
11713356 2001
11
Identification of R146225 as a novel, orally active inhibitor of interleukin-5 biosynthesis. 61 54
11046102 2000
12
Pulmonary eosinophilia and production of MIP-1alpha are prominent responses to infection with pneumonia virus of mice. 61 54
10753501 2000
13
Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. 61 54
10590259 1999
14
Antigen-induced airway hyperresponsiveness, pulmonary eosinophilia, and chemokine expression in B cell-deficient mice. 54 61
10030835 1999
15
An essential role for interleukin-5 and eosinophils in helminth-induced airway hyperresponsiveness. 54 61
9712797 1998
16
IgE down regulation and cytokine induction by Aspergillus antigens in human allergic bronchopulmonary aspergillosis. 54 61
9523846 1998
17
Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. 61 54
9802959 1998
18
Kinetics of the development and recovery of the lung from IgE-mediated inflammation: dissociation of pulmonary eosinophilia, lung injury, and eosinophil-active cytokines. 61 54
9032176 1997
19
Cytokines as targets for the inhibition of eosinophilic inflammation. 54 61
9352584 1997
20
Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. 61 54
8985399 1997
21
The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. 54 61
8818342 1996
22
Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. 61 54
8784786 1996
23
Immunopurification and measurement of IgE in serum samples from bancroftian filariasis patients. 61 54
8627493 1996
24
Rapid and selective induction of blood eosinophilia in guinea pigs by recombinant human interleukin 5. 54 61
8664444 1995
25
Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5. 54 61
7613159 1995
26
Animal models of occupational asthma. 61 54
8013613 1994
27
Allergic bronchopulmonary mycosis complicating cystic fibrosis. 54 61
1475542 1992
28
Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. 61 54
2010556 1991
29
Frequency analysis of IgE-secreting B lymphocytes in persons with normal or elevated serum IgE levels. 61 54
1899687 1991
30
The BALB/c mouse as a model for immunological studies of microfilariae-induced pulmonary eosinophilia. 61 54
2382764 1990
31
Acidic Calcium-Independent Phospholipase A2 Regulates Eosinophil-Mediated Pathology during Filarial Manifestation of Tropical Pulmonary Eosinophilia. 61
33441441 2021
32
Unusual presentation of chronic eosinophilic pneumonia with mild peripheral eosinophilia. 61
33542024 2021
33
Approach to Eosinophilia Presenting With Pulmonary Symptoms. 61
33002503 2021
34
Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. 61
33450293 2021
35
Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. 61
33434111 2021
36
Sertraline-Induced Acute Eosinophilic Pneumonia. 61
33457126 2020
37
Leukotriene D4 paradoxically limits LTC4-driven platelet activation and lung immunopathology. 61
33285161 2020
38
Microfilaria-dependent thoracic pathology associated with eosinophilic and fibrotic polyps in filaria-infected rodents. 61
33160409 2020
39
Acute Eosinophilic Pneumonia Induced by Switching from Conventional Cigarette Smoking to Heated Tobacco Product Smoking. 61
32713912 2020
40
Ustekinumab associated chronic eosinophilic pneumonia. 61
32962463 2020
41
Oral administration of Hsp65-producing Lactococcus lactis attenuates allergic asthma in a murine model. 61
33124086 2020
42
Conserved T-cell epitopes of respiratory syncytial virus (RSV) delivered by recombinant live attenuated influenza vaccine viruses efficiently induce RSV-specific lung-localized memory T cells and augment influenza-specific resident memory T-cell responses. 61
32585323 2020
43
The role of HRCT in Tropical Pulmonary Eosinophilia. 61
32823149 2020
44
Lung fibroblasts produce IL-33 in response to stimulation with retinoblastoma-binding protein 9 via production of prostaglandin E2. 61
32484881 2020
45
Exon 8 KIT mutation and pulmonary eosinophilia. 61
32168380 2020
46
Eosinophilic Pneumonia and Lymphadenopathy Associated With Vaping and Tetrahydrocannabinol Use. 61
32217740 2020
47
Filarial tropical pulmonary eosinophilia. 61
30720371 2020
48
Unilateral antibiotic-induced acute eosinophilic pneumonia on the operative side after surgery for primary lung cancer: a case report. 61
32076875 2020
49
Pleuroparenchymal Fibroelastosis Associated with Crohn's Disease: A New Aetiology? 61
33457362 2020
50
Acute eosinophilic pneumonia associated with non-cigarette smoking products: a systematic review. 61
32383466 2020

Variations for Pulmonary Eosinophilia

Expression for Pulmonary Eosinophilia

Search GEO for disease gene expression data for Pulmonary Eosinophilia.

Pathways for Pulmonary Eosinophilia

Pathways related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 SERPINA1 RNASE3 RNASE2 PRG2 IL5 IL4
2
Show member pathways
13.76 PRG2 IL5 IL4 IL13 CXCL8 CSF2
3
Show member pathways
13.61 IL5 IL4 IL13 CXCL8 CSF2 CCR3
4
Show member pathways
13.52 IL5 IL4 IL13 CXCL8 CCL7 CCL5
5
Show member pathways
13.38 PRG2 CXCL8 CCR3 CCL7 CCL5 CCL3
6
Show member pathways
13.33 IL5 IL4 IL13 CXCL8 CSF2 CCL5
7
Show member pathways
13.32 IL5 IL4 IL13 CXCL8 CSF2 CCR3
8
Show member pathways
13.13 IL5 IL4 IL13 CXCL8 CSF2 CCR3
9
Show member pathways
12.85 CXCL8 CSF2 CCR3 CCL5 CCL3
10
Show member pathways
12.84 CXCL8 CCR3 CCL7 CCL5 CCL3 CCL17
11
Show member pathways
12.8 RNASE3 PRG2 IL5 IL4 IL13 EPX
12
Show member pathways
12.35 IL5 IL4 IL13 CSF2
13
Show member pathways
12.33 CXCL8 CCR3 CCL7 CCL5 CCL11
14
Show member pathways
12.25 CXCL8 CCR3 CCL7 CCL5 CCL3 CCL17
15
Show member pathways
12.19 IL5 IL4 IL13 CXCL8 CSF2 CCL7
16
Show member pathways
12.16 SFTPD IL4 CXCL8 CCL11
17 11.98 IL5 IL4 CSF2 CCR3
18 11.97 IL4 IL13 CXCL8 CCL11
19 11.87 CXCL8 CSF2 CCL5 CCL3
20 11.82 IL5 IL4 CSF2
21 11.79 IL5 IL4 IL13 CCL3
22 11.79 IL5 IL4 IL13 CXCL8 CSF2
23
Show member pathways
11.76 IL5 IL4 CXCL8 CSF2
24 11.66 IL5 IL4 CCL17 CCL11
25 11.46 IL5 IL4 IL13 CCL17 CCL11
26 11.32 IL4 IL13 CXCL8 CSF2 CCL5 CCL3
27 11.31 IL5 IL4 IL13
28 11.26 IL5 IL4 IL13 CSF2
29 11.2 IL5 IL4 IL13
30 11.12 SERPINA1 IL5 IL4 IL13 CXCL8 CSF2
31 10.8 IL5 IL4 IL13
32 10.6 PRG2 IL5 IL4 IL13 CXCL8 CSF2

GO Terms for Pulmonary Eosinophilia

Cellular components related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 SFTPD SERPINA1 RNASE3 RNASE2 PRG2 IL5
2 extracellular space GO:0005615 9.5 SFTPD SERPINA1 RNASE3 RNASE2 IL5 IL4

Biological processes related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.29 PDE4A IL5 IL4 CYSLTR1 CXCL8 CCR3
2 G protein-coupled receptor signaling pathway GO:0007186 10.2 PDE4A CYSLTR1 CXCL8 CCR3 CCL7 CCL5
3 positive regulation of gene expression GO:0010628 10.05 IL4 IL13 CXCL8 CSF2 CCL3
4 neutrophil degranulation GO:0043312 10.04 SERPINA1 RNASE3 RNASE2 PRG2 EPX
5 positive regulation of GTPase activity GO:0043547 10.03 CCL7 CCL5 CCL3 CCL17 CCL11
6 positive regulation of cell migration GO:0030335 10 IL4 CCL7 CCL5 CCL3 CCL11
7 MAPK cascade GO:0000165 9.98 IL5 CSF2 CCL5 CCL3
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.98 CCL7 CCL5 CCL3 CCL17 CCL11
9 defense response to bacterium GO:0042742 9.96 SFTPD RNASE3 PRG2 EPX
10 cell-cell signaling GO:0007267 9.95 CCL7 CCL5 CCL3 CCL17
11 cellular response to tumor necrosis factor GO:0071356 9.95 CXCL8 CCL7 CCL5 CCL3 CCL17 CCL11
12 cytokine-mediated signaling pathway GO:0019221 9.92 IL5 IL4 IL13 CXCL8 CSF2 CCL5
13 cellular calcium ion homeostasis GO:0006874 9.91 CCL7 CCL5 CCL3 CCL11
14 cellular response to interferon-gamma GO:0071346 9.91 CCL7 CCL5 CCL3 CCL17 CCL11
15 inflammatory response GO:0006954 9.91 IL5 IL13 CXCL8 CCR3 CCL7 CCL5
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 IL4 IL13 CSF2 CCL5
17 cellular response to interleukin-1 GO:0071347 9.88 CXCL8 CCL7 CCL5 CCL3 CCL17 CCL11
18 monocyte chemotaxis GO:0002548 9.85 CCL7 CCL5 CCL3 CCL17 CCL11
19 neutrophil chemotaxis GO:0030593 9.85 CXCL8 CCL7 CCL5 CCL3 CCL17 CCL11
20 cell chemotaxis GO:0060326 9.84 CCR3 CCL5 CCL3
21 calcium-mediated signaling GO:0019722 9.83 CXCL8 CCR3 CCL3
22 lymphocyte chemotaxis GO:0048247 9.83 CCL7 CCL5 CCL3 CCL17 CCL11
23 positive regulation of B cell proliferation GO:0030890 9.8 IL5 IL4 IL13
24 eosinophil chemotaxis GO:0048245 9.8 CCL7 CCL5 CCL3 CCL11
25 innate immune response in mucosa GO:0002227 9.79 RNASE3 RNASE2 IL4
26 macrophage chemotaxis GO:0048246 9.74 SFTPD CCL5 CCL3
27 macrophage activation GO:0042116 9.73 IL4 IL13 CSF2
28 immune response GO:0006955 9.73 PRG2 IL5 IL4 IL13 CXCL8 CSF2
29 positive regulation of natural killer cell chemotaxis GO:2000503 9.71 CCL7 CCL5 CCL3
30 induction of bacterial agglutination GO:0043152 9.7 SFTPD RNASE3 RNASE2
31 chemokine-mediated signaling pathway GO:0070098 9.7 CXCL8 CCR3 CCL7 CCL5 CCL3 CCL17
32 dendritic cell differentiation GO:0097028 9.68 IL4 CSF2
33 negative regulation of G protein-coupled receptor signaling pathway GO:0045744 9.68 CXCL8 CCL5
34 negative regulation by host of viral transcription GO:0043922 9.67 CCL5 CCL3
35 neutrophil activation GO:0042119 9.67 CXCL8 CCL5
36 positive regulation of podosome assembly GO:0071803 9.65 IL5 CSF2
37 positive regulation of mast cell degranulation GO:0043306 9.64 IL4 IL13
38 negative regulation of complement-dependent cytotoxicity GO:1903660 9.62 IL4 IL13
39 positive regulation of cellular biosynthetic process GO:0031328 9.62 CXCL8 CCL5
40 chemotaxis GO:0006935 9.32 RNASE3 RNASE2 CYSLTR1 CXCL8 CCR3 CCL7

Molecular functions related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR chemokine receptor binding GO:0048020 9.55 CCL7 CCL5 CCL3 CCL17 CCL11
2 CCR1 chemokine receptor binding GO:0031726 9.43 CCL7 CCL5 CCL3
3 chemokine activity GO:0008009 9.43 CXCL8 CCL7 CCL5 CCL3 CCL17 CCL11
4 CCR5 chemokine receptor binding GO:0031730 9.4 CCL5 CCL3
5 phospholipase activator activity GO:0016004 9.37 CCL5 CCL3
6 CCR4 chemokine receptor binding GO:0031729 9.32 CCL5 CCL17
7 cytokine activity GO:0005125 9.32 IL5 IL4 IL13 CXCL8 CSF2 CCL7

Sources for Pulmonary Eosinophilia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....